Welcome to OncoGeneX

News & Events

Thursday, May 2 2013

OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013

Wednesday, May 1 2013

OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in...

Tuesday, Apr 30 2013

OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment

OncoGenex is a biopharmaceutical company uniquely focused on cancer treatment resistance. We are committed to the development and commercialization of first-in-class, innovative therapies that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.

Product Pipeline

Phase Three

Custirsen is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer types of cancer and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy.

Phase Two

OGX-427 is a second generation antisense drug which, in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27), a cell survival protein found at elevated levels in many human cancers. The development program for OGX-427 aims to demonstrate inhibition of Hsp27 can lead to improved prognosis and treatment outcomes for cancer patients.